Roberto Nitsch

Company: AstraZeneca

Job title: Associate Director

Seminars:

VIRTUAL: Innovating CRISPR Gene Editing Safety Assessments 11:30 am

Most gene editing applications carry the risk of unfavourable outcomes The level of unwanted gene editing consequences is still highly unknown The safety of gene therapies depends on the accuracy of editing detectionRead more

day: Day One